JCNRJournal of Clinical and Nursing Research2208-36852208-3693Bio-Byword Scientific Publishing Pty. Ltd.10.26689/jcnr.v9i7.11479ArticleThe Emerging Influence of Intestinal Microecological Dynamics on the Pathogenesis and Progression of Hepatic Chronic Pathologies: Current Scientific Perspectiveshttps://artdesignp.com/journal/JCNR/9/7/10.26689/jcnr.v9i7.11479QinShaoyan2025972025-08-04The intestinal microbiome, often characterized as humanity’s “secondary genome,” possesses a genetic repertoire that dwarfs the coding capacity of the human genome by orders of magnitude. The essential architecture of this system is constituted by a vast phylogenetic tapestry of luminal microorganisms, whose dynamic symbiosis serves as a critical determinant of intestinal mucosal homeostasis and functional fidelity. The past decade has witnessed a paradigm shift in biomedical sciences, wherein technological breakthroughs in microbial single-cell genomics and spatial metatranscriptomics have unveiled the gut ecosystem’s pivotal role in host physiology. Emerging evidence from gut-liver interface research demonstrates how microbial-derived signals, facilitated by the portal circulatory nexus, mechanistically contribute to the initiation and perpetuation of chronic hepatopathies. This review elucidates the pathophysiological mechanisms through which intestinal dysbiosis propagates chronic hepatopathies, with the ultimate objective of informing novel diagnostic paradigms and therapeutic interventions.

Gan C, Yuan Y, Shen H, et al., 2025, Liver Diseases: Epidemiology, Causes, Trends and Predictions. Signal Transduction and Targeted Therapy, 10(1): 33.

Marrapu S, Kumar R, 2024, Chronic Hepatitis B: Prevent, Diagnose, and Treat Before the Point of No Return. World Journal of Hepatology, 16(10): 1151–1157.

Huang DQ, Singal AG, Kono Y, et al., 2022, Changing Global Epidemiology of Liver Cancer From 2010 to 2019: NASH Is the Fastest Growing Cause of Liver Cancer. Cell Metabolism, 34(7): 969–977.

Soriano V, Alvarez C, Edagwa B, et al., 2022, Ultra-Long-Acting (XLA) Antivirals for Chronic Viral Hepatitis. International Journal of Infectious Diseases, 114: 45–50.

Chen Y, Zhou J, Wang L, 2021, Role and Mechanism of Gut Microbiota in Human Disease. Frontiers in Cellular and Infection Microbiology, 11: 625913.

Sebastián Domingo JJ, Sánchez Sánchez C, 2018, From the Intestinal Flora to the Microbiome. Revista Espanola De Enfermedades Digestivas, 110(1): 51–56.

Ren Z, Li A, Jiang J, et al., 2019, Gut Microbiome Analysis as a Tool Towards Targeted Non-Invasive Biomarkers for Early Hepatocellular Carcinoma. Gut, 68(6): 1014–1023.

Li X, Wu S, Du Y, et al., 2020, Entecavir Therapy Reverses Gut Microbiota Dysbiosis Induced by Hepatitis B Virus Infection in a Mouse Model. International Journal of Antimicrobial Agents, 56(1): 106000.

Zhu Q, Xia P, Zhou X, et al., 2019, Hepatitis B Virus Infection Alters Gut Microbiota Composition in Mice. Frontiers in Cellular and Infection Microbiology, 9: 377.

Chou HH, Chien WH, Wu LL, et al., 2015, Age-Related Immune Clearance of Hepatitis B Virus Infection Requires the Establishment of Gut Microbiota. Proceedings of the National Academy of Sciences of the United States of America, 112(7): 2175–2180.

Kauppila JH, Karttunen TJ, Saarnio J, et al., 2013, Short DNA Sequences and Bacterial DNA Induce Esophageal, Gastric, and Colorectal Cancer Cell Invasion. Apmis, 121(6): 511–522.

Krieg AM, 2006, Therapeutic Potential of Toll-Like Receptor 9 Activation. Nature Reviews Drug Discovery, 5(6): 471–484.

Lin L, Zhang J, 2017, Role of Intestinal Microbiota and Metabolites on Gut Homeostasis and Human Diseases. BMC Immunology, 18(1): 2.

Pinchera B, Scotto R, Zappulo E, et al., 2023, Impact of Oral Antiviral Therapy Against HCV on Gut Microbiota: A Prospective Study. New Microbiologica, 46(2): 196–201.

Guo W, Zhou X, Li X, et al., 2021, Depletion of Gut Microbiota Impairs Gut Barrier Function and Antiviral Immune Defense in the Liver. Frontiers in Immunology, 12: 636803.

Jiang Y, Zhang T, Kusumanchi P, et al., 2020, Alcohol Metabolizing Enzymes, Microsomal Ethanol Oxidizing System, Cytochrome P450 2E1, Catalase, and Aldehyde Dehydrogenase in Alcohol-Associated Liver Disease. Biomedicines, 8(3): 50.

Yuan R, Tao X, Liang S, et al., 2018, Protective Effect of Acidic Polysaccharide From Schisandra Chinensis on Acute Ethanol-Induced Liver Injury Through Reducing CYP2E1-Dependent Oxidative Stress. Biomedicine & Pharmacotherapy, 99: 537–542.

Wang Y, Liu Y, Sidhu A, et al., 2012, Lactobacillus Rhamnosus GG Culture Supernatant Ameliorates Acute Alcohol-Induced Intestinal Permeability and Liver Injury. American Journal of Physiology Gastrointestinal and Liver Physiology, 303(1): G32–41.

Mutlu EA, Gillevet PM, Rangwala H, et al., 2012, Colonic Microbiome Is Altered in Alcoholism. American Journal of Physiology Gastrointestinal and Liver Physiology, 302(9): G966–978.

Kirpich IA, Solovieva NV, Leikhter SN, et al., 2008, Probiotics Restore Bowel Flora and Improve Liver Enzymes in Human Alcohol-Induced Liver Injury: A Pilot Study. Alcohol, 42(8): 675–682.

Shen S, Wang K, Zhi Y, et al., 2022, Gypenosides Counteract Hepatic Steatosis and Intestinal Barrier Injury in Rats With Metabolic Associated Fatty Liver Disease by Modulating the Adenosine Monophosphate Activated Protein Kinase and Toll-Like Receptor 4/Nuclear Factor Kappa B Pathways. Pharmaceutical Biology, 60(1): 1949–1959.

Guo Q, Li Y, Dai X, et al., 2023, Polysaccharides: The Potential Prebiotics for Metabolic Associated Fatty Liver Disease (MAFLD). Nutrients, 15(17): 3722.

Yang C, Xu J, Xu X, et al., 2023, Characteristics of Gut Microbiota in Patients With Metabolic Associated Fatty Liver Disease. Scientific Reports, 13(1): 9988.

Le Chatelier E, Nielsen T, Qin J, et al., 2013, Richness of Human Gut Microbiome Correlates With Metabolic Markers. Nature, 500(7464): 541–546.

Wang Y, Pan CQ, Xing H, 2019, Advances in Gut Microbiota of Viral Hepatitis Cirrhosis. BioMed Research International, 2019: 9726786.

Zhao ZH, Xin FZ, Xue Y, et al., 2019, Indole-3-Propionic Acid Inhibits Gut Dysbiosis and Endotoxin Leakage to Attenuate Steatohepatitis in Rats. Experimental & Molecular Medicine, 51(9): 1–14.

Peng K, Dong W, Luo T, et al., 2023, Butyrate and Obesity: Current Research Status and Future Prospect. Frontiers in Endocrinology, 14: 1098881.

Li F, Ye J, Shao C, et al., 2021, Compositional Alterations of Gut Microbiota in Nonalcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis. Lipids in Health and Disease, 20(1): 22.

Kullberg RFJ, Wiersinga WJ, Haak BW, 2021, Gut Microbiota and Sepsis: From Pathogenesis to Novel Treatments. Current Opinion in Gastroenterology, 37(6): 578–585.

Rao BC, Lou JM, Wang WJ, et al., 2020, Human Microbiome Is a Diagnostic Biomarker in Hepatocellular Carcinoma. Hepatobiliary & Pancreatic Diseases International, 19(2): 109–115.

Zhou D, Chen YW, Zhao ZH, et al., 2018, Sodium Butyrate Reduces High-Fat Diet-Induced Non-Alcoholic Steatohepatitis Through Upregulation of Hepatic GLP-1R Expression. Experimental & Molecular Medicine, 50(12): 1–12.

Mei X, Li Y, Zhang X, et al., 2024, Maternal Phlorizin Intake Protects Offspring From Maternal Obesity-Induced Metabolic Disorders in Mice via Targeting Gut Microbiota to Activate the SCFA-GPR43 Pathway. Journal of Agricultural and Food Chemistry, 72(9): 4703–4725.

Zhao ZH, Wang ZX, Zhou D, et al., 2021, Sodium Butyrate Supplementation Inhibits Hepatic Steatosis by Stimulating Liver Kinase B1 and Insulin-Induced Gene. Cellular and Molecular Gastroenterology and Hepatology, 12(3): 857–871.

Li NN, Li W, Feng JX, et al., 2021, High Alcohol-Producing Klebsiella Pneumoniae Causes Fatty Liver Disease Through 2,3-Butanediol Fermentation Pathway In Vivo. Gut Microbes, 13(1): 1979883.

Lu Y, George J, 2024, Interaction Between Fatty Acid Oxidation and Ethanol Metabolism in Liver. American Journal of Physiology Gastrointestinal and Liver Physiology, 326(5): G483–G494.

Tsurusaki S, Tsuchiya Y, Koumura T, et al., 2019, Hepatic Ferroptosis Plays an Important Role as the Trigger for Initiating Inflammation in Nonalcoholic Steatohepatitis. Cell Death & Disease, 10(6): 449.

Zheng Z, Wang B, 2021, The Gut-Liver Axis in Health and Disease: The Role of Gut Microbiota-Derived Signals in Liver Injury and Regeneration. Frontiers in Immunology, 12: 775526.

Astbury S, Atallah E, Vijay A, et al., 2020, Lower Gut Microbiome Diversity and Higher Abundance of Proinflammatory Genus Collinsella Are Associated With Biopsy-Proven Nonalcoholic Steatohepatitis. Gut Microbes, 11(3): 569–580.

Liu Y, Chen Z, Li C, et al., 2025, Associations Between Changes in the Gut Microbiota and Liver Cirrhosis: A Systematic Review and Meta-Analysis. BMC Gastroenterology, 25(1): 16.

Chen Y, Fang H, Chen H, et al., 2025, Bifidobacterium Inhibits the Progression of Colorectal Tumorigenesis in Mice Through Fatty Acid Isomerization and Gut Microbiota Modulation. Gut Microbes, 17(1): 2464945.

Kebbe M, Leung K, Perrett B, et al., 2025, Effects of Infant Formula Supplemented With Prebiotics on the Gut Microbiome, Gut Environment, Growth Parameters, and Safety and Tolerance: A Systematic Review and Meta-Analysis. Nutrition Reviews, 83(3): 422–447.

Chen S, Zhang D, Li D, et al., 2025, Microbiome Characterization of Patients With Crohn Disease and the Use of Fecal Microbiota Transplantation: A Review. Medicine, 104(4): e41262.

Wang P, Wang R, Zhao W, et al., 2025, Gut Microbiota-Derived 4-Hydroxyphenylacetic Acid From Resveratrol Supplementation Prevents Obesity Through SIRT1 Signaling Activation. Gut Microbes, 17(1): 2446391.

Bhatia Z, Kumar S, Seshadri S, 2025, Fecal Microbiota Transplantation as a Potential Therapeutic Approach to Improve Impaired Glucose Tolerance Via Gut Microbiota Modulation in Rat Model. Journal of Diabetes & Metabolic Disorders, 24(1): 28.

Ooijevaar RE, Terveer EM, Verspaget HW, et al., 2019, Clinical Application and Potential of Fecal Microbiota Transplantation. Annual Review of Medicine, 70: 335–351.

Zeng S, Schnabl B, 2024, Gut Mycobiome Alterations and Implications for Liver Diseases. PLOS Pathogens, 20(8): e1012377.